🟢 REGN is trading 4.1% up today as Benchmark upgrades to Buy on pipeline strength

REGN is trading 4.1% up at $676.58 as investors respond to a fresh analyst upgrade and look past a one-time Q2 IPR&D charge to the long-term pipeline story.

• Benchmark raised the stock to a Buy rating, highlighting significant undervaluation and a robust drug portfolio.
• Investors are shrugging off a previously announced $127 million R&D hit to earnings, focusing instead on the company's clinical development prospects.
• The upgrade reinforces market confidence in the long-term growth potential of the company's core pharmaceutical assets.